Format

Send to

Choose Destination
Sci Rep. 2014 Nov 14;4:7058. doi: 10.1038/srep07058.

Comparative effectiveness of Di'ao Xin Xue Kang capsule and Compound Danshen tablet in patients with symptomatic chronic stable angina.

Author information

1
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, No. 16 Nanxiaojie, Dongzhimen nei, Beijing, 100700, China.
2
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, AnShan Xi Road 314, Nankai District, 300193, Tianjin, China.
3
The Second Hospital Affiliated to Liaoning University of TCM, HuangHe North Road 60, Huanggu District, Shenyang 110034, Liaoning, China.
4
The TCM Hospital of Xinjiang Uygur Autonomous Region, HuangHe Road 116, Wulumuqi 830099, Xinjiang, China.
5
The Jilin Provincial Hospital of Integrated TCM and Western Medicine, Gongnong Da Road 1745, Chaoyang District, Changchun 130021, Jilin, China.
6
School of Public Health, Southeast University, Dijia Qiao 87, Nanjing 210009, Jiangsu, China.
7
The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, No.37 Twelve Road, Chengdu 610075, Sichuan, China.
8
Changzhou TCM Hospital, Heping North Road, Tianing District, Changzhou 213004, Jiangsu, China.

Abstract

A high proportion of patients with stable angina remains symptomatic despite multiple treatment options. Di'ao Xinxuekang (XXK) capsule and Compound Danshen (CDS) tablet have been approved for treating angina pectoris for more than 20 years in China. We compare the anti-anginal effectiveness of XXK capsule and CDS tablet in patients with symptomatic chronic stable angina. A randomized, multicenter, double-blind, parallel-group, superiority trial was conducted in 4 study sites. 733 patients with symptomatic chronic stable angina were included in the full analysis set. The primary outcomes were the proportion of patients who were angina-free and the proportion of patients with normal electrocardiogram (ECG) recordings during 20 weeks treatment. Compared with CDS, XXK significantly increased the proportion of angina-free patients, but no significant difference was noted in the proportion of patients with normal ECG recordings. Weekly angina frequency and nitroglycerin use were significantly reduced with XXK versus CDS at week 20. Moreover, XXK also improved the quality of life of angina patients as measured by the SAQ score and Xueyu Zheng (a type of TCM syndrome) score. We demonstrate that XXK capsule is more effective for attenuating anginal symptoms and improving quality of life in patients with symptomatic chronic stable angina, compared with CDS tablet.

PMID:
25394847
PMCID:
PMC4231340
DOI:
10.1038/srep07058
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center